HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.

Abstract
Aurora kinases and cyclin-dependent kinases, which play critical roles in the cell cycle and are frequently overexpressed in a variety of tumors, have been suggested as attractive targets for cancer therapy. JNJ-7706621, a recently identified dual inhibitor of these kinases, is reported to induce cell cycle arrest, endoreduplication, and apoptosis. In the present study, we further investigated the molecular mechanisms underlying these effects. The inhibitor arrested various cells at G2 phase at low concentration, and at both G1 and G2 phases at high concentration. JNJ-7706621 did not prevent localization of Aurora A to the spindle poles, but did inhibit other centrosomal proteins such as TOG, Nek2, and TACC3 in early mitotic phase. Similarly, the drug did not prevent localization of Aurora B to the kinetochore, but did inhibit other chromosomal passenger proteins such as Survivin and INCENP. In the cells exposed to JNJ-7706621 after nocodazole release, Aurora B, INCENP, and Survivin became relocated to the peripheral region of chromosomes, but Plk1 and Prc1 were localized on microtubules in later mitotic phase. Treatment of nocodazole-synchronized cells with JNJ-7706621 was able to override mitotic arrest by preventing spindle checkpoint signaling, resulting in failure of chromosome alignment and segregation. Injection of the drug significantly inhibited the growth of TC135 Ewing's sarcoma cells transplanted into athymic mice by cell cycle arrest and apoptosis. JNJ-7706621 is a unique inhibitor regulating cell cycle progression at multiple points, suggesting that it could be useful for cell cycle analysis and therapy of various cancers, including Ewing's sarcoma.
AuthorsA Matsuhashi, T Ohno, M Kimura, A Hara, M Saio, A Nagano, G Kawai, M Saitou, I Takigami, K Yamada, Y Okano, K Shimizu
JournalCurrent cancer drug targets (Curr Cancer Drug Targets) Vol. 12 Issue 6 Pg. 625-39 (Jul 2012) ISSN: 1873-5576 [Electronic] Netherlands
PMID22463590 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • JNJ-7706621
  • Protein Kinase Inhibitors
  • Triazoles
  • Tubulin Modulators
  • AURKB protein, human
  • Aurka protein, mouse
  • Aurkb protein, mouse
  • Aurora Kinase A
  • Aurora Kinase B
  • Aurora Kinases
  • Protein-Serine-Threonine Kinases
  • Cyclin-Dependent Kinases
  • Nocodazole
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Aurora Kinase A
  • Aurora Kinase B
  • Aurora Kinases
  • Bone Neoplasms (drug therapy, enzymology, pathology)
  • Cell Cycle Checkpoints (drug effects)
  • Cell Proliferation (drug effects)
  • Cyclin-Dependent Kinases (antagonists & inhibitors, metabolism)
  • Cytokinesis (drug effects)
  • Dose-Response Relationship, Drug
  • HeLa Cells
  • Humans
  • Mice
  • Mice, Nude
  • Mitosis (drug effects)
  • Neoplasms (drug therapy, enzymology, pathology)
  • Nocodazole (pharmacology)
  • Protein Kinase Inhibitors (pharmacology)
  • Protein Transport
  • Protein-Serine-Threonine Kinases (antagonists & inhibitors, metabolism)
  • Sarcoma, Ewing (drug therapy, enzymology, pathology)
  • Spindle Apparatus (drug effects, enzymology)
  • Time Factors
  • Triazoles (pharmacology)
  • Tubulin Modulators (pharmacology)
  • Tumor Burden
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: